Skip to main content

Table 1 Description of baseline survey data. The study sites are given with the baseline sample size and microfilariae (mf) prevalence (%), blood volumes collected during the survey to test for mf positivity, annual biting rate (ABR) of vector mosquitoes, dominant vector species and drug regimen used for simulating the chemotherapeutic interventions by mass drug administration (MDA) without/with vector control (VC)

From: Bayesian calibration of simulation models for supporting management of the elimination of the macroparasitic disease, Lymphatic Filariasis

Study villages

Mf Sample size

Blood volume

(μl)

cMf (%)

dBaseline ABR

CFA sample size

CFA (%)

Mosquito species (genus)

aDrug regimen

bDrug’s efficacies (ω, ε, TP)

Source

Peneng

63

1000

66.67

8194

-

-

An.

DEC + ALB

(55, 95, 6)

[10, 18, 78, 79]

Albulum

50

1000

80

42328

-

-

An.

DEC + ALB

(55, 95, 6)

[10, 18, 78, 79]

Yauatong

131

1000

92.37

37052

-

-

An.

DEC + ALB

(55, 95, 6)

[10, 18, 78, 79]

Nanaha

211

1000

54.98

11611

-

-

An.

DEC + ALB

(55, 95, 6)

[10, 18, 78, 79]

Ngahmbule

346

1000

51.16

4346

-

-

An.

DEC + ALB

(55, 95, 6)

[10, 18, 78, 79]

Tawalani

367

100

35.72

12850

-

-

An.

IVM + ALB

(35, 99, 9)

[80]

eJaribuni

1007

100

25.35

15677

-

-

An.

IVM + ALB

(35, 99, 9)

[81, 82]

Tingrela

699

20

63.89

4156

-

-

An.

IVM + ALB

(35, 99, 9)

[83]

Chiconi

245

20

58.90

10586

-

-

An.

IVM + ALB

(35, 99, 9)

[84]

eMasaika

848

100

28.61

6184

837

52.2

An.

IVM + ALB

(35, 99, 9)

[85]

eKirare

919

100

28.18

2090

90

53.3

An.

IVM + ALB

(35, 99, 9)

[86]

eAlebtong

739

100

33.47

58292

890

29.1

An.

IVM + ALB

(35, 99, 9)

[87]

eLwala

572

100

21.05

16341

896

18.3

An.

IVM + ALB

(35, 99, 9)

[87]

eObalanga

799

100

34.62

4587

900

30.1

An.

IVM + ALB

(35, 99, 9)

[87]

eKingwede

825

100

3.07

1548

-

-

Cx.

IVM + ALB

(35, 99, 9)

[85]

eMao

546

100

27.8

25439

-

-

Cx.

IVM + ALB

(35, 99, 9)

[80]

eMambrui

787

100

24.99

4964

-

-

Cx.

IVM + ALB

(35, 99, 9)

[81, 82]

Pondicherry

1549

20

34.74

88500

-

-

Cx.

DEC + ALB

(55, 95, 6)

[88]

Calcutta

861

20

26.72

115942

-

-

Cx.

DEC + ALB

(55, 95, 6)

[89, 90]

Vettavallam

7976

20

22.83

100375

-

-

Cx.

DEC + ALB

(55, 95, 6)

[91]

Pakistan

1443

20

31.49

1607

-

-

Cx.

DEC + ALB

(55, 95, 6)

[92, 93]

Jakarta

922

20

12.27

223000

-

-

Cx.

DEC + ALB

(55, 95, 6)

[94]

  1. An.: Anopheles mosquitoes; Cx.: Culex mosquitoes; Drug’s efficacies (ω,ε, T P ): (instantaneous kill rate (%) for adult worms, instantaneous kill rate (%) for mf, drug’s efficacy period in months); mf (%): mf prevalence in percentages calculated from the number of mf-positive samples out of the total individuals sampled (sample size) in a study site; DEC: diethylcarbamazine citrate; IVM: Ivermectin; ALB: Albendazole.
  2. aThe combination drug regimens used for MDA simulations in each site areas are as recommended for each site region by the WHO [95, 96].
  3. bDrug efficacy values are taken from [3].
  4. cAll mf prevalence values were standardized to reflect sampling of 1 ml blood volumes using a transformation factor of 1.95 and 1.15 respectively for values originally estimated using 20 or 100 μl blood volumes [49].
  5. dBaseline ABR are used to obtain the monthly biting rate (MBR = ABR/12), which is used as inputs into the LF models described in the text. The symbol (−) indicates that the baseline CFA data are either not available or available but not broken by age-groups.
  6. eThese sites have mixed vector species: here they are represented by the dominant vector species.